更新于：2024-11-01

Hyperopia

远视

更新于：2024-11-01

基本信息

别名

Far-sightedness、Farsighted、Farsightedness

+ [22]

简介

A refractive error in which rays of light entering the eye parallel to the optic axis are brought to a focus behind the retina, as a result of the eyeball being too short from front to back. It is also called farsightedness because the near point is more distant than it is in emmetropia with an equal amplitude of accommodation. (Dorland, 27th ed)

关联

项与远视相关的药物

Obinutuzumab

奥妥珠单抗

靶点

CD20

作用机制

CD20抑制剂 [+3]

在研机构

Janssen-Cilag Ltd. [+19]

原研机构

Roche Glycart AG

在研适应症

CD20阳性B细胞慢性淋巴细胞白血病 [+45]

非在研适应症

CD20阳性弥漫性大B细胞淋巴瘤 [+14]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2013-11-01

Vitamin B2

维生素B2

靶点-

作用机制-

在研机构

iniuva

原研机构-

在研适应症

核黄素缺乏 [+1]

非在研适应症

散光 [+3]

最高研发阶段批准上市

首次获批国家/地区-

首次获批日期1800-01-20

NVK-033

靶点-

作用机制-

在研机构

Vyluma, Inc.

原研机构-

在研适应症

远视

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

161

项与远视相关的临床试验

NCT06483113 / Not yet recruitingN/A

DAILIES TOTAL1® Soft Contact Lenses - Post-Market Clinical Follow-up Study

The purpose of this study is to continuously assess the visual performance and safety of DAILIES TOTAL1 soft contact lenses in a real world setting and broader patient base through routine clinical practices. This activity will be used to continuously support delefilcon A (sphere, toric, and multifocal) soft contact lens regulatory requirements and standards.

开始日期2024-11-01

申办/合作机构

Alcon Research Ltd.

NCT06408649 / Not yet recruitingN/A

Post-market Clinical Follow-up Study of Alcon TOTAL30® Spherical Contact Lenses (Lehfilcon A) and TOTAL30® for Astigmatism Contact Lenses (Lehfilcon A)

The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to continuously assess the visual performance and safety of TOTAL30 Sphere and TOTAL30 for Astigmatism contact lenses in a real-world setting across a broad variety of patients through routine clinical practices.

开始日期2024-10-01

申办/合作机构

Alcon Research Ltd.

NCT06597292 / Not yet recruitingN/A

Vision Improvement for Patients With Presbyopia

The VIS Opti-K Low Vision Aid device will be used to provide vision improvement to patients with refractive disorders (hyperopia and presbyopia).

开始日期2024-09-16

申办/合作机构-

100 项与远视相关的临床结果

登录后查看更多信息

100 项与远视相关的转化医学

登录后查看更多信息

0 项与远视相关的专利（医药）

登录后查看更多信息

4,582

项与远视相关的文献（医药）

2025-01-01·American Journal of Ophthalmology

Spectacle Lenses With Highly Aspherical Lenslets for Slowing Axial Elongation and Refractive Change in Low-Hyperopic Chinese Children: A Randomized Controlled Trial

Article

作者: Chen, Can ; Zhang, Zhe ; Gu, Dantong ; Wang, Bingjie ; Wang, Xiaoying ; Watt, Kathleen ; Chen, Zhi ; Yang, Danjuan ; Zhou, Jiaqi ; Zhou, Xueyi ; Chen, Zhuoyi ; Zhou, Xingtao ; Kang, Pauline ; Zeng, Li

PURPOSESpectacle lenses with highly aspherical lenslets (HAL) have been shown to effectively retard myopia progression in myopic children. This study aimed to investigate the impact of spectacle lenses with HAL on refractive and axial length (AL) changes in Chinese children with low amount of hyperopia.DESIGNRandomized controlled trial.METHODSA total of 108 Chinese children aged 6.0 to 9.9 years and spherical equivalent refractive error (SERE) from 0.00 to +2.00 D were randomly allocated into two groups: the HAL group and the single vision spectacle lens (SVL) group. Cycloplegic refraction, AL, and uncorrected visual acuity were measured at baseline, 6 and 12 months after lens dispensing. The duration of spectacle lens wear was monitored using a wearable device attached to the spectacle frame and by questionnaire logs provided by participants at each follow-up visit.RESULTSThe 1-year SERE change was -0.19 (-0.32, 0.03) D and -0.23 (-0.36, 0.05) D in the SVL and HAL groups (P = .883). The 1-year AL elongation was 0.24 (0.18, 0.34) mm and 0.19 (0.12, 0.27) mm in the SVL and HAL groups (P = .057). In the HAL group, changes in AL and SERE were significantly correlated to lens wearing time (P < .001 and P = .024, respectively). Participants in the HAL group who wore their lenses for more than 30 hours per week had significantly slower AL elongation (0.11 [0.05, 0.17] mm) compared to their SVL counterparts (0.27 [0.21, 0.33] mm) (P < .001).CONCLUSIONSSpectacle lenses with HAL significantly reduced AL elongation in low hyperopic children who wore lenses for over 30 hours per week. A dose-response relationship was evident with longer lens wearing time associated with less AL change.

2024-12-31·International Journal of Qualitative Studies on Health and Well-being

Family caregiver experiences and needs across health conditions, relationships, and the lifespan: a Qualitative analysis

Article

作者: Terrill, Alexandra L ; Utz, Rebecca L ; Ellington, Lee ; Dassel, Kara B ; Scammon, Debra L ; Kirby, Anne V ; Wickens, Emily ; Neller, Sarah A ; Hebdon, Megan Thomas

PURPOSEThe purpose of this study was to understand the lived experiences of family caregivers who provide care to individuals across a broad range of ages, caregiving relationships, and health conditions and/or disabilities. Family caregiver research is typically siloed by health condition or by caregiving relationship, leaving gaps in understanding similarities and differences among caregivers.METHODSWe hosted three virtual focus groups with diverse family caregivers (n = 26) caring for an individual with a long-term disability and/or health condition(s). We conducted a qualitative thematic analysis using an iterative, inductive process.RESULTSParticipants primarily expressed shared experiences, despite having unique caregiving situations. We identified themes among a) caregiver experiences: Trying to Do It All, Balancing Complex Emotions, Managing Expectations, and Adjusting to Changes Over Time and b) caregiver needs: Longing for Breaks and Self-Care; Lacking Help, Support and Resources; and Desiring Understanding and Recognition.CONCLUSIONSThese findings emphasize that many elements of the caregiving experience transcend care recipient age, condition, and relationship and are applicable to clinicians, researchers, and policy makers. The evidence of shared caregiver experiences can guide efficiencies in policy and practice (e.g., pooling of existing resources, expansion of interventions) to meet the needs of a broader population of caregivers.

2024-12-01·Cellular and Molecular Neurobiology

Drivers of Chronic Pathology Following Ischemic Stroke: A Descriptive Review

Review

作者: Goodman, Grant W ; Ritzel, Rodney M ; Tan, Chunfeng ; Do, Trang H

Stroke is the third leading cause of death and long-term disability in the world. Considered largely a disease of aging, its global economic and healthcare burden is expected to rise as more people survive into advanced age. With recent advances in acute stroke management, including the expansion of time windows for treatment with intravenous thrombolysis and mechanical thrombectomy, we are likely to see an increase in survival rates. It is therefore critically important to understand the complete pathophysiology of ischemic stroke, both in the acute and subacute stages and during the chronic phase in the months and years following an ischemic event. One of the most clinically relevant aspects of the chronic sequelae of stroke is its extended negative effect on cognition. Cognitive impairment may be related to the deterioration and dysfunctional reorganization of white matter seen at later timepoints after stroke, as well as ongoing progressive neurodegeneration. The vasculature of the brain also undergoes significant insult and remodeling following stroke, undergoing changes which may further contribute to chronic stroke pathology. While inflammation and the immune response are well established drivers of acute stroke pathology, the chronicity and functional role of innate and adaptive immune responses in the post-ischemic brain and in the peripheral environment remain largely uncharacterized. In this review, we summarize the current literature on post-stroke injury progression, its chronic pathological features, and the putative secondary injury mechanisms underlying the development of cognitive impairment and dementia. We present findings from clinical and experimental studies and discuss the long-term effects of ischemic stroke on both brain anatomy and functional outcome. Identifying mechanisms that occur months to years after injury could lead to treatment strategies in the chronic phase of stroke to help mitigate stroke-associated cognitive decline in patients.

项与远视相关的新闻（医药）

2024-10-14

·米内网

【关注】DHA“双子星”！新华制药新品上市

精彩内容有“脑黄金”之称的DHA，是大脑和视网膜的重要构成成分。数据显示，2022年全球DHA市场规模超过50亿美元。继“金”系列三款鱼油产品取得阶段性成果后，新华制药又将目光对准高纯度DHA鱼油原料，围绕“健脑”、“护眼”等大众普遍关注的健康诉求，打造了两款DHA产品，进一步完善公司在鱼油领域的前瞻布局。深海鱼油是提取DHA的主要路径之一。早在2013年，新华制药就进军高纯度药用鱼油的研发领域，依托于强大的研发能力和技术支持，新华制药攻克了高纯度药用鱼油的关键技术，鱼油分离技术达到国际先进水平，目前已具备生产各种中高端鱼油产品的能力，在此基础上开发了高纯EPA系列、高纯DHA系列以及高纯混合系列产品，且原料已经出口到美国、欧洲、日本等国家和地区。值得一提的是，新华制药的鱼油原料选用全球四大渔场之一的秘鲁渔场的单一凤尾鱼，原料入厂前均由国际权威检测机构对有机污染物、农药残留、重金属、核辐射等消费者普遍关注的项目进行全面检测，保证了源头的品质纯净。鱼油DHA凝胶糖果，DHA+PS双成分结合，成就健脑好帮手大脑是人体的神经中枢系统。随着人们保健意识提升，脑健康已经成为人们日常的关注重点，大脑健康补充剂市场正在快速扩张。大脑健康补充剂的主要消费者为老年人及学生。受年龄影响，老年人容易患上阿尔茨海默氏症、偏头痛、帕金森氏症、失眠症等神经系统疾病，而学生的学习压力大，用脑频率高，对脑健康产品也有着较大的需求。 Grand View Research市场数据显示，2021年大脑健康补充剂市场规模为76.8亿美元，预计2022年至2030年将以8.3%的复合年增长率增长，2030年全球脑保健补充剂市场规模预计将达到157.4亿美元。目前市面上大多数的脑健康产品均含有磷脂酰丝氨酸(PS)，PS是存在于细菌、酵母、植物、哺乳动物细胞中的一种重要的膜磷脂，是大脑神经细胞的重要组成部分，能改善老年人阿尔茨海默病、改善记忆和认知能力、抗抑郁、抗压抑、辅助激活酶等[1][2]。新华制药的新品——鱼油DHA凝胶糖果，主要由300mgDHA+20mgPS组成，适合老年人及经常用脑、有改善记忆需求的学生群体。叶黄素酯鱼油DHA凝胶糖果，3大成分呵护视力健康俗话说，“眼睛是心灵的窗户”。然而随着互联网的发展、工作学习时间加长、人口老龄化进程加快等，眼健康问题已成为不可忽视的健康问题。目前常见的眼健康问题包括屈光不正（主要为近视、远视、老花眼及散光）、干眼症、白内障、视网膜疾病、青光眼等。据国家卫健委和国家统计局数据测算，2022年我国屈光不正患者超7亿人，干眼症患者近3.6亿人，白内障患者2.2亿人。此外，视疲劳、斜弱视等眼视光健康问题也很普遍。研究发现，DHA在视网膜和神经细胞膜中占比达到50%，具有改善视力、保护视网膜的功效，DHA可以促进视觉色素再生，对因用眼过度引起的视觉疲倦、青光眼、老花眼、白内障等眼部问题有明显改善[3]；叶黄素和玉米黄质共同形成视网膜黄斑色素，均可在人的视网膜黄斑区自然沉积以形成保护层，通过过滤蓝光和抗氧化作用，来保护视网膜神经免受光氧化损伤，延缓一系列视网膜和晶状体病变的发展，最终预防或推迟年龄相关性眼部疾病和黄斑色素异常的发生[4][5]。巨大的需求撑起广阔的蓝海市场。根据《眼科药物市场发展现状与未来趋势研究报告》显示，2016年至2020年，全球眼科药物市场规模从277亿美元增长至327亿美元，复合年增长率为4.2%。预计2025年将达到464亿美元，2030年将达到739亿美元。而在膳食补充剂方面，2023年7月-2024年8月，天猫跟淘宝上的海外叶黄素累计销售额分别超过6000万元、4000万元；普通膳食中的叶黄素/蓝莓/越橘提取物累计销售额分别超过6亿元、5000万元。新华制药的新品——叶黄素酯鱼油DHA凝胶糖果，含有300mgDHA，再搭配上10mg叶黄素酯以及2mg玉米黄质，三种成分强强联合，非常适合经常面对电脑、手机的青中年以及有年龄相关性眼部疾病的老年人。结语作为拥有80多年历史的红色制药企业，新华制药始终秉承与时俱进的时代创新精神，致力于成为国内高纯度鱼油领域的开创者和先行者。未来，立足技术、专业专注的新华制药还会在鱼油领域带来怎样的惊喜？让我们拭目以待。参考文献：[1].PS软胶囊改善记忆的药效学研究沈阳药科大学学报第37卷第12期2020年12月[2].磷脂酰丝氨酸研究进展食品工业科技 Vol.29 No.05 2008[3].二十二碳六烯酸运载体系的制备、表征与展望《中国食品添加剂》 2024年第4期[4].AREDS2ResearchGroup.“Lutein/ZeaxanthinandOmega-3FattyAcidsforAge-RelatedEyeDiseaseStudy2(AREDS2)ControlledRandomizedClinicalTrial.”JAMA,publishedonlineMay5,2013.[5].叶黄素和玉米黄质对眼睛的保护作用研究进展江苏农业科学2013年第41卷第9期声明：本文谨供行业人士参考，消费者请参照药品说明书或遵医嘱购买，内容的合法合规性由作者或委托发布方承担。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 ●温馨提示● 因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下：【分享、点赞、在看】点一点不失联哦

上市批准

2024-09-24

·爱尔康中国

爱尔康视觉模拟器：开启共情之窗，连接多元视界

爱尔康视觉模拟器：开启共情之窗，连接多元视界爱尔康视觉模拟器爱尔康视觉模拟器是一款基于H5和深度学习的创新工具，旨在提高公众对视力疾病的认识。它模拟九种常见眼疾，让用户体验不同程度的视觉障碍，并展示爱尔康的人工晶体和个性化屈光矫正技术。通过多样化的场景和实时相机模式，用户可以较为直观地感受眼疾对日常生活的影响。这个工具不仅展示了爱尔康的技术创新，还促进了对视力障碍者的理解和关怀。爱尔康视觉模拟器微信H5版每一次眨眼，都是一次与世界的对话。然而，对全球十亿视力障碍者而言，这对话变得模糊不清、扭曲变形或光怪陆离。他们在朦胧、畸变或黑暗的世界中孤独探索，与我们所见的世界截然不同。多种眼疾模拟状态图片展示作为全球眼科领域的领导者，我们深谙视力健康的重要性。近80年来，我们不懈努力，致力于帮助患者恢复清晰视界。同时，我们也竭力提高公众对视力健康的关注，搭建起视力障碍群体与健康人群之间相互理解、关爱的桥梁。随着数字技术的飞速发展，眼科护理迎来了全新可能。这些技术不仅赋能一流的诊疗服务，还让用户能直观体验各种眼疾的影响。从全球服务的AcrySof® IOL Vision Simulator网页呈现，到myalcon.com的数字化服务，爱尔康的数字化进程同样突飞猛进。 SMART Educator IOL Vision Guide Alcon 结合中国最普及的社交平台和用户对移动端交互的明显偏好，爱尔康（Alcon）致力于以更贴近用户的方式传播我们的数字化方案。我们选择了用户最常使用、最便于分享的微信平台，通过爱尔康视觉模拟器，不仅展示与人们息息相关的眼疾表现，还呈现我们在中国市场上各种创新人工晶体技术的最新成果。 01 无需注册、无需安装，关注爱尔康中国公众号即可一键启用爱尔康视觉模拟器大大简化了使用体验。无需安装或注册，用户只需关注爱尔康中国的微信公众号，点击”视觉模拟器”，即可开启一段视力探索之旅。 02 模拟九大常见眼科疾病实时呈现不同症状程度的视觉效果爱尔康视觉模拟器模拟了九种常见眼疾：近视、远视、散光、白内障、飞蚊症、青光眼、红绿色弱、红绿色盲和全色盲。只需一键点击，您就能实时体验这些眼疾的视觉效果，较为直观地感受视力障碍患者眼中的世界。通过截屏或录屏分享这些不同视力人群的视角，我们不仅能深化对各种视力障碍的理解，还能促进人们对眼睛健康和视力多样性的尊重与关怀。爱尔康视觉模拟器实时呈现9种常见眼疾通过调节滑块，用户可以实时观察并体验不同程度眼疾对视力的影响。这种互动式的设计让人仿佛置身于患者的视角中，更好地感受视力障碍的各种程度和表现。从轻微到严重，用户可以体验视力逐渐模糊、变形或受限的过程，深入理解不同程度的眼疾对日常生活的影响。爱尔康视觉模拟器实时视力疾病程度调节 03 科技叠戴，一键体验爱尔康白内障人工晶状体和个性化屈光手术方案通过爱尔康视力模拟器，您可以体验人工晶体、个性化屈光矫正等不同眼健康产品及技术对视力的改善效果。选择叠戴模拟，直观地感受到不同类型的人工晶体产品如何优化您的视觉体验。并通过“了解爱尔康解决方案”，获悉我们在中国成功纳入国家集采目录的人工晶体技术及个性化屈光解决方案。在爱尔康视觉模拟器中，模拟近视散光患者的视野叠戴爱尔康“全光塑”个性化定制近视手术模拟效果在爱尔康视觉模拟器中，模拟白内障视野叠戴景深延长人工晶体的模拟效果 04 内置多种日常场景体验不同环境和光线下的视觉效果视觉模拟器内置了丰富多样的场景，涵盖日常生活、户外活动、工作环境和家庭聚会等各种情境。这些精心设计的场景不仅包括不同的时间段（如清晨、正午和夜晚），还考虑了各种光线条件（如自然光、人工照明和昏暗环境）。通过这些丰富的场景设置，用户能够多方位感受不同环境和光线条件下的视觉效果，更真实地体验各种眼部疾病对日常生活的影响。视觉模拟器基于8大生活工作场景叠加视觉效果 05 开启相机模式实时模拟眼前画面（限量开放）在爱尔康视觉模拟器中，启用摄像头后，您可以实时体验各种眼部疾病对视野的影响。模拟器将眼部疾病的状况直接应用于摄像头画面，支持前后置摄像头切换、横竖屏模式切换和实时画面生成。这种模拟让用户能直观地感受眼部疾病对视觉的影响，仿佛透过镜头进入患者的世界。爱尔康视觉模拟器相机模式下，实时渲染视频数据通过与微信社交生态的无缝整合和先进人工智能技术的应用，爱尔康视力模拟器为用户带来了前所未有的沉浸式体验。爱尔康的目标远不止于展示产品和技术。我们致力于通过这一创新工具传播品牌理念，积极推广眼健康教育。通过让用户亲身体验不同眼疾的视觉效果，我们旨在唤起公众对眼健康重要性的深刻认知。同时，这种互动式的教育方式也有助于消除对视力障碍者的误解，促进社会包容。我们相信，只有让更多人真正理解视力健康的重要性，才能激发他们主动关注和保护自己的眼睛，并对他人的视力状况保持同理心和关怀。 CN-CORPVIV-2400006

siRNA

2024-08-29

·PRNewswire

ZEISS innovation paves way to more personalized patient care with cutting-edge AI technology and industry-leading surgical solutions

Showcasing at ESCRS from Sept. 6 to 10, in Barcelona, Spain: REFRACTIVE INDUSTRY MILESTONES: ZEISS extends its global refractive industry momentum with more than 10 million eyes treated with ZEISS SMILE and ZEISS SMILE pro; ZEISS announces first treatment in the CE market for hyperopia with lenticule extraction using ZEISS SMILE pro technology. NEW DIGITAL & SURGICAL ENHANCEMENTS IN THE OR: Expanded portfolio of advanced optical and digital ophthalmic microscopes introduced in CE markets with ZEISS ARTEVO 750 and ZEISS ARTEVO 850. EXCELLENT IOL CLINICAL RESULTS: ZEISS showcases its advanced ZEISS IOL portfolio, including new clinical results with the AT ELANA 841P trifocal IOL and its innovative ZEISS trifocal technology, highlighting excellent visual outcomes. AI ADVANCEMENTS FOR CATARACT PATIENTS: ZEISS brings data-driven IOL power calculations to European cataract market with CE mark for the ZEISS AI IOL Calculator; ZEISS CIRRUS PathFinder provides fully integrated AI decision support through automated OCT assessment for pre-operative cataract patients (pending CE mark); ZEISS Surgery Optimizer features AI-based video segmentation to review, analyze, and share surgery videos post-surgery. JENA, Germany, Aug. 29, 2024 /PRNewswire/ -- ZEISS Medical Technology will showcase its latest cataract and corneal refractive workflow innovations at the European Society of Cataract and Refractive Surgeons (ESCRS) conference. ZEISS leads the industry as the first medical device manufacturer to offer treatment for hyperopia with lenticule extraction using SMILE® pro in the CE markets. ZEISS is also celebrating its latest refractive milestone of surpassing the 10 million mark for lenticule extraction procedures performed with ZEISS SMILE and ZEISS SMILE pro. Building on its surgical technology, ZEISS will introduce its advanced optical and digital ophthalmic microscopes to the CE markets, as well as showcase its enhanced IOL portfolio including new clinical results with the AT ELANA® 841P trifocal IOL. Additionally, the company will show its latest AI technology within the ZEISS Cataract Workflow, including the CE-marked ZEISS AI IOL Calculator and the pending-CE-mark CIRRUS® PathFinder™ AI tool for improved pre-operative patient care. Both solutions highlight how digital technologies within the ZEISS Medical Ecosystem are continuing to set the pace for clinical workflow innovation and foretelling how AI technology will support more personalized patient care in the future. Continue Reading Industry Milestone: More Than 10 Million Eyes Treated with ZEISS SMILE and ZEISS SMILE pro ZEISS CIRRUS PathFinder (awaiting CE mark, not available in all countries) ZEISS AI IOL Calculator on ZEISS EQ Workplace Hyperopia Indication for ZEISS SMILE pro